Cite

HARVARD Citation

    Tripathy, D. et al. (n.d.). 155PPooled efficacy analysis of first-line ribociclib (RIB) plus endocrine therapy (ET) in HR+/HER2: Advanced breast cancer (ABC). Annals of oncology. p. . [Online]. 
  
Back to record